Azitra is an early-stage clinical-stage biopharmaceutical company developing topical therapies for skin diseases using genetically engineered bacteria. The core technology involves engineering strains of *Staphylococcus epidermidis*, a naturally occurring skin bacterium, to colonize the skin and secrete therapeutic proteins below the stratum corneum — bypassing the skin's natural barrier to topically applied drugs. Azitra's three lead programs target rare or underserved dermatological conditions: ATR-12 is a topical ointment for Netherton syndrome, a rare and often fatal infant skin disease with no approved treatment, currently in Phase 1b trials; ATR-04 targets the papulopustular rash affecting cancer patients on EGFR inhibitor drugs, with its first patient dosed in 2025; and ATR-01 targets ichthyosis vulgaris, a chronic scaly skin disease affecting an estimated 1.3M Americans, currently in IND-enabling studies. Azitra holds an exclusive worldwide license for the SyMPL genetic engineering platform from Fred Hutchinson Cancer Center, which enables transformation of previously difficult-to-engineer bacterial species. The company has no commercial revenue and relies on contract manufacturers for clinical supply. If approved, Azitra plans to sell products directly in the U.S. through a focused sales force targeting dermatologists and oncologists, with international markets potentially addressed through partnerships or licensing deals.